Alibaba Health Information Technology Ltd. (HK:0241)
HKEX:0241
Holding HK:0241?
Track your performance easily

Alibaba Health Information Technology (0241) Stock Forecast & Price Target

4 Followers
See the Price Targets and Ratings of:

0241 Analyst Ratings

Moderate Buy
2Ratings
2 Buy
0 Hold
0 Sell
Based on 2 analysts giving stock ratings to
Alibaba
Health Information Technology
in the past 3 months
TipRanks enables you to focus on the analyst rating consensus of all analysts or only the top performers​ in the past 3 months

0241 Stock 12 Month Forecast

Average Price Target

HK$4.35
▼(-22.33% Downside)
Based on 2 Wall Street analysts offering 12 month price targets for Alibaba Health Information Technology in the last 3 months. The average price target is HK$4.35 with a high forecast of HK$4.50 and a low forecast of HK$4.20. The average price target represents a -22.33% change from the last price of HK$5.60.
{"navigator":{"disabled":true},"exporting":{"enabled":false},"title":{"text":null},"chart":{"height":200,"style":{"fontFamily":"Roboto Flex","fontWeight":"400","color":"#5d5d5e"},"spacingTop":30,"spacingRight":60,"events":null},"yAxis":{"labels":{"style":{"color":"inherit"},"distance":6,"x":-6,"y":-6,"zIndex":1,"map_label_formatter":{"1":"HK$1","6":"HK$6","2.25":"HK$2.25","3.5":"HK$3.5","4.75":"HK$4.75"}},"plotLines":[{"color":"rgba(0,0,0,0)","value":4.49999988474015,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":-10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-bottom flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#199ca5\">High </span>\n\n  <span style=\"color:#199ca5\">HK$4.50</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":4.3495256,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":0,"text":"<div  class=\"positionrelative hoverZ3 triangleleft flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#828080\">Average </span>\n\n  <span style=\"color:#828080\">HK$4.35</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":4.19999989242414,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-top flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#912767\">Low </span>\n\n  <span style=\"color:#912767\">HK$4.20</span>\n  </div></div>","useHTML":true}}],"tickPositions":[1,2.25,3.5,4.75,6],"lineColor":"#dddddd","gridLineWidth":1,"gridLineColor":"#dddddd","lineWidth":1,"title":{"text":""}},"plotOptions":{"series":{"states":{"inactive":{"opacity":1}}},"line":{"animation":{"duration":0},"dataLabels":{"allowOverlap":true},"borderWidth":1,"marker":{"enabled":true,"fillColor":"#FFFFFF","radius":3,"lineWidth":2,"symbol":"circle","lineColor":"#828080"}}},"xAxis":{"labels":{"style":{"color":"inherit"},"rotation":0,"map_label_formatter":{"3":"Jan<br/>2024","6":"Apr<br/>2024","9":"Jul<br/>2024","12":"Oct<br/>2024","25":"Oct<br/>2025"}},"tickPositions":[3,6,9,12,25],"plotLines":[{"color":"#dddddd","width":1,"value":12},{"color":"#dddddd","width":1,"value":12}],"lineWidth":0,"gridLineWidth":1,"gridLineColor":"#dddddd","tickLength":0},"legend":{"symbolRadius":0,"symbolPadding":4,"symbolHeight":14,"borderWidth":0,"symbolWidth":14,"align":"left","verticalAlign":"bottom","enabled":false},"tooltip":{"backgroundColor":"rgba(0,0,0,0)","useHTML":true,"borderWidth":0,"borderColor":"rgba(0,0,0,0)","padding":0,"shadow":null,"headerFormat":"","footerFormat":"","pointFormat":"<div class=\"flexccc lineHeight2 bgwhite shadow2 px3 py3 radiismall fonth10_semibold\">\n                <span class=\"colorgray-3 mb4\">{point.date:%b %d ,%Y}</span>\n                <span>Analyst Consensus</span>\n                {point.info}\n          </div>\n           </div>"},"credits":{"enabled":false},"accessibility":{"description":""},"responsive":{"rules":[{"chartOptions":{"chart":{"spacing":[0,0,0,0],"margin":[30,60,40,5]},"xAxis":{"tickPositions":[3,12,25.25]},"yAxis":{"labels":{"enabled":false}},"title":{"text":null},"subtitle":{"text":null}},"condition":{"maxWidth":500}}]},"series":[{"lineWidth":2,"dashStyle":"ShortDash","name":"High","type":"line","color":"#199ca5","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,5.6,5.515384606518473,5.430769213036946,5.346153819555419,5.261538426073892,5.176923032592366,5.092307639110839,5.007692245629311,4.923076852147784,4.8384614586662575,4.753846065184731,4.669230671703204,4.584615278221677,{"y":4.49999988474015,"marker":{"fillColor":"#199ca5","lineColor":"#199ca5","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Average","type":"line","color":"#828080","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,5.6,5.503809661538461,5.407619323076923,5.311428984615384,5.215238646153846,5.1190483076923075,5.022857969230769,4.926667630769231,4.830477292307692,4.734286953846153,4.638096615384615,4.5419062769230765,4.445715938461539,{"y":4.3495256,"marker":{"fillColor":"#828080","lineColor":"#828080","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Low","type":"line","color":"#912767","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,5.6,5.4923076840326255,5.384615368065252,5.276923052097878,5.169230736130505,5.061538420163131,4.953846104195756,4.846153788228383,4.738461472261009,4.630769156293635,4.523076840326262,4.415384524358887,4.307692208391514,{"y":4.19999989242414,"marker":{"fillColor":"#912767","lineColor":"#912767","enabled":true,"symbol":"circle"}}]},{"type":"line","data":[{"y":4.8,"date":1696550400000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Moderate Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 1,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":4.84,"date":1698969600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Moderate Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 1,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":4.37,"date":1701388800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 3,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":3.87,"date":1704412800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Moderate Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 3,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 1</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":2.85,"date":1706832000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Moderate Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 3,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 1</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":3.46,"date":1709251200000,"info":" <span style=\"color:#828080\" class=\"mb3 mt2 fonth8_semibold\"> Hold</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 1,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 1</span>\n      ","marker":{"lineColor":"#828080","enabled":true,"symbol":"circle"}},{"y":2.8,"date":1712275200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Moderate Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 1,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":3.28,"date":1714694400000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Moderate Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 1,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":3.86,"date":1717718400000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Moderate Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 2,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":3.19,"date":1720137600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 3,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":3.18,"date":1722556800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 3,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":2.9,"date":1725580800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Moderate Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 1,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":5.6,"date":1728000000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Moderate Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 2,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"fillColor":"black","lineColor":"black","enabled":true,"symbol":"circle"}},null,null,null,null,null,null,null,null,null,null,null,null],"color":"#0666a7"}]}
Highest Price TargetHK$4.50Average Price TargetHK$4.35Lowest Price TargetHK$4.20
The highest, average, and lowest price target of all analysts. Click on ‘Top Analysts’ to focus on the best performers.

Detailed List of Analyst Forecasts​

Ranks
Any
Any
Analyst Rating
Any
Any
Upside/ Downside
Any
Any
Action
Any
Any
Analyst Profile
Expert Firm
Price Target
Position
Upside / Downside
Action
Date
Follow
Article
Goldman Sachs
HK$4.4
Buy
-21.43%
Downside
Initiated
06/18/24
Alibaba Health resumed with a Buy at Goldman SachsAlibaba Health resumed with a Buy at Goldman Sachs
Macquarie
HK$3.6
Hold
-35.71%
Downside
Reiterated
06/07/24
Macquarie Reiterates Neutral Rating on Alibaba Health (241:HK) (BABA)Macquarie analyst John Wang reiterated a Neutral rating and HK$3.60 price target on Alibaba Health (241:HK) (NYSE: BABA).
Morgan Stanley
HK$5
Sell
-10.71%
Downside
Reiterated
01/05/24
Analysts Offer Insights on Healthcare Companies: Alibaba Health Information Technology (Other OTC: ALBHF) and Insmed (NASDAQ: INSM)
Jefferies
HK$8.2
Buy
46.43%
Upside
Reiterated
12/03/23
Buy Rating Affirmed for Alibaba Health on Strong Financials and Strategic Acquisition
Citi
HK$9.5HK$8
Buy
42.86%
Upside
Reiterated
12/01/23
Alibaba Health (241:HK) (BABA) PT Lowered to HK$8 at CitiCiti analyst Cui Cui lowered the price target on Alibaba Health (241:HK) (NYSE: BABA) to HK$8.00 (from HK$9.50) while maintaining a Buy rating.
UBS
HK$6.5HK$5
Hold
-10.71%
Downside
Reiterated
10/24/23
Alibaba Health (241:HK) PT Lowered to HK$5 at UBSUBS analyst Henry Liu lowered the price target on Alibaba Health (241:HK) to HK$5.00 (from HK$6.50) while maintaining a Neutral rating.

Best Analysts Covering Alibaba Health Information Technology

Which Analyst Should I Follow If I Want to Buy HK:0241 and Sell After:
1 Month
xxx
Success Rate
2/4 ratings generated profit
50%
Average Return
+10.40%
reiterated a xxx
rating 12 days ago
Copying xxxxxxxxxxxxxxxxxx
trades and holding each position for 1 Month would result in 50.00% of your transactions generating a profit, with an average return of +10.40% per trade.
3 Months
xxx
Success Rate
1/4 ratings generated profit
25%
Average Return
+4.10%
reiterated a xxx
rating 12 days ago
Copying xxxxxxxxxxxxxxxxxx
trades and holding each position for 3 Months would result in 25.00% of your transactions generating a profit, with an average return of +4.10% per trade.
1 Year
Success Rate
3/4 ratings generated profit
75%
Average Return
+36.88%
reiterated a buy rating 12 days ago
Copying Charlene Liu's trades and holding each position for 1 Year would result in 75.00% of your transactions generating a profit, with an average return of +36.88% per trade.
2 Years
xxx
Success Rate
4/4 ratings generated profit
100%
Average Return
+50.02%
reiterated a xxx
rating 12 days ago
Copying xxxxxxxxxxxxxxxxxx
trades and holding each position for 2 Years would result in 100.00% of your transactions generating a profit, with an average return of +50.02% per trade.
The Best Analyst Covering tool allows you to follow the analysts who have the best success rates and average returns on a specific stock. Only analysts that gave a Buy or Sell rating on the stock in the past 12 months are eligible for inclusion in this tool. Follow the analysts of your choice to receive real-time updates when they publish a new rating.

0241 Analyst Recommendation Trends

Rating
Jan 24
Apr 24
May 24
Jun 24
Sep 24
Strong Buy
3
2
3
4
5
Buy
0
0
0
0
0
Hold
1
1
1
2
2
Sell
1
1
1
0
0
Strong Sell
0
0
0
0
0
total
5
4
5
6
7
In the current month, 0241 has received 5 Buy Ratings, 2 Hold Ratings, and 0 Sell Ratings. 0241 average Analyst price target in the past 3 months is HK$4.35.
Each month's total comprises the sum of three months' worth of ratings.
Stocks with the Highest Top Analyst Consensus in the Healthcare Sector
Find stocks in the Healthcare sector that are highly recommended by Top Performing Analysts.

0241 Financial Forecast

0241 Earnings Forecast

Next quarter’s earnings estimate for 0241 is HK$0.07 with a range of HK$0.07 to HK$0.07. The previous quarter’s EPS was HK$0.07. 0241 beat its EPS estimate 100.00% of the time in the past 12 months, while its overall industry beat the EPS estimate 39.74% of the time in the same period. In the last calendar year 0241 has Outperformed its overall industry.
Next quarter’s earnings estimate for 0241 is HK$0.07 with a range of HK$0.07 to HK$0.07. The previous quarter’s EPS was HK$0.07. 0241 beat its EPS estimate 100.00% of the time in the past 12 months, while its overall industry beat the EPS estimate 39.74% of the time in the same period. In the last calendar year 0241 has Outperformed its overall industry.

0241 Sales Forecast

Next quarter’s sales forecast for 0241 is HK$16.51B with a range of HK$16.51B to HK$16.51B. The previous quarter’s sales results were HK$15.26B. 0241 beat its sales estimates 50.00% of the time in past 12 months, while its overall industry beat sales estimates 43.36% of the time in the same period. In the last calendar year 0241 has Outperformed its overall industry.
Next quarter’s sales forecast for 0241 is HK$16.51B with a range of HK$16.51B to HK$16.51B. The previous quarter’s sales results were HK$15.26B. 0241 beat its sales estimates 50.00% of the time in past 12 months, while its overall industry beat sales estimates 43.36% of the time in the same period. In the last calendar year 0241 has Outperformed its overall industry.

0241 Stock Forecast FAQ

What is HK:0241’s average 12-month price target, according to analysts?
Based on analyst ratings, Alibaba Health Information Technology Ltd.’s 12-month average price target is HK$4.35.
    What is HK:0241’s upside potential, based on the analysts’ average price target?
    Currently there's no upside potential for HK:0241, based on the analysts’ average price target.
    Can I see which stocks the top-ranking analysts are rating?
    Yes, go to the Analysts’ Top Stocks tool to see stocks with a Strong Buy or Strong Sell analyst rating consensus, according to the top performers.
      How can I follow the stock ratings of top Wall Street analysts?
      Head over to our Expert Center to see a list of the top 100 Wall Street analysts and follow the analysts of your choice. Visit their profiles for more details about their stock ratings and see how they perform on a stock-by-stock basis.
        Is Alibaba Health Information Technology Ltd. a Buy, Sell or Hold?
        Alibaba Health Information Technology Ltd. has a consensus rating of Moderate Buy, which is based on 2 buy ratings, 0 hold ratings and 0 sell ratings.
          What is Alibaba Health Information Technology Ltd.’s share price target?
          The average share price target for Alibaba Health Information Technology Ltd. is HK$4.35. This is based on 2 Wall Streets Analysts 12-month price targets, issued in the past 3 months.
          The highest analyst share price target is HK$4.50 ,and the lowest forecast is HK$4.20. The average share price target represents -22.33% Decrease from the current price of HK$5.6.
            What do analysts say about Alibaba Health Information Technology Ltd.?
            Alibaba Health Information Technology Ltd.’s analyst rating consensus is a Moderate Buy. This is based on the ratings of 2 Wall Streets Analysts.
              How can I buy shares of Alibaba Health Information Technology Ltd.?
              To buy shares of HK:0241, you can open a brokerage account. See exclusive account opening deals on our Best Online Brokers page.
                What am I Missing?
                Make informed decisions based on Top Analysts' activity
                Know what industry insiders are buying
                Get actionable alerts from top Wall Street Analysts
                Find out before anyone else which stock is going to shoot up
                Get powerful stock screeners & detailed portfolio analysis